Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin mesylate + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Eribulin mesylate + gemcitabine + cisplatin** is a triple-drug chemotherapy regimen studied primarily in advanced solid tumors, notably in locally advanced or metastatic bladder cancer. Eribulin mesylate is a synthetic microtubule inhibitor, gemcitabine is a nucleoside analog that inhibits DNA synthesis, and cisplatin is a platinum-based agent that forms DNA crosslinks, all three contributing to enhanced cancer cell death through distinct mechanisms. Preclinical data show cytotoxic synergy among these agents. This combination is used intravenously, with eribulin and gemcitabine administered on days 1 and 8, and cisplatin on day 1 of a 21-day cycle, and has demonstrated tolerability and preliminary clinical efficacy in early-phase trials for bladder cancer[1][3].
- Brand names
- Halaven (eribulin mesylate)Gemzar (gemcitabine)Platinol (cisplatin)
- Other names
- eribulin mesylate + gemcitabine + cisplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyDNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on eribulin mesylate + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin mesylate + gemcitabine + cisplatin.